Citigroup Inc. Lowers Stock Position in Repligen Corporation $RGEN

Key Points

• Citigroup Inc. reduced its stake in Repligen Corporation by 95.3% in the first quarter, owning only 57,302 shares after selling over 1.1 million shares.
• Repligen reported $0.37 earnings per share for the quarter, missing estimates, but had revenue growth of 14.8% year-over-year with total revenue of $182.37 million.
• Analysts have a consensus rating of "Moderate Buy" on Repligen with a target price of $169.45, indicating potential for growth despite recent fluctuations in stock ownership.

Citigroup Inc. decreased its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 95.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,302 shares of the biotechnology company's stock after selling 1,168,824 shares during the quarter. Citigroup Inc. owned about 0.10% of Repligen worth $7,291,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its stake in Repligen by 4.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 396,150 shares of the biotechnology company's stock worth $50,406,000 after acquiring an additional 18,250 shares during the period. Intrust Bank NA bought a new position in Repligen in the first quarter worth $222,000. Geneva Capital Management LLC raised its holdings in Repligen by 5.9% in the first quarter. Geneva Capital Management LLC now owns 143,543 shares of the biotechnology company's stock worth $18,264,000 after purchasing an additional 7,958 shares in the last quarter. Argent Trust Co bought a new position in Repligen in the first quarter worth $212,000. Finally, Bank of Nova Scotia bought a new position in Repligen in the first quarter worth $2,149,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Buying and Selling at Repligen

In related news, Director Martin D. Madaus acquired 1,800 shares of the stock in a transaction dated Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director directly owned 1,800 shares in the company, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.20% of the stock is currently owned by insiders.

Repligen Stock Performance

NASDAQ:RGEN traded down $1.9350 on Wednesday, hitting $121.5650. The stock had a trading volume of 202,783 shares, compared to its average volume of 776,837. The stock has a market cap of $6.84 billion, a price-to-earnings ratio of -486.74, a price-to-earnings-growth ratio of 2.28 and a beta of 1.05. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The business's 50-day simple moving average is $122.16 and its two-hundred day simple moving average is $132.13. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. During the same period in the previous year, the business posted $0.40 earnings per share. The company's revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a report on Tuesday, April 29th. Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Royal Bank Of Canada increased their price objective on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a report on Wednesday, July 30th. Barclays assumed coverage on Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price objective for the company. Finally, Wells Fargo & Company decreased their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $169.45.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.